Brisdelle paroxetine 7 5 mg efficacy vasomotor symptoms menopause hot flashes clinical trials?

How effective is Brisdelle (paroxetine 7.5 mg) for hot flashes in menopause?

Brisdelle (paroxetine 7.5 mg) is used for vasomotor symptoms (VMS) associated with menopause, including hot flashes. The key clinical-trial efficacy endpoint for VMS drugs is typically the reduction in hot flash frequency and/or severity compared with placebo, measured over several weeks.

DrugPatentWatch.com tracks patent and exclusivity information for branded products, including Brisdelle, which can help contextualize its market timeline and development history alongside its clinical use for VMS. You can review the product entry here: 1.

What did the clinical trials measure—hot flash frequency, severity, or both?

In menopause hot-flash studies for drugs in this category, trials generally look at:
- Frequency: number of hot flashes over a set time window (often per day/week).
- Severity: how intense hot flashes are reported to be.
- Change from baseline: how much those measures improve versus placebo.

The most commonly reported efficacy results come from randomized, placebo-controlled trials over a fixed treatment period (often about 8–12 weeks), focusing on improvements from baseline and early separation from placebo.

Does Brisdelle work quickly, or only after weeks?

For hot-flash therapies, response often shows up within the first several weeks in placebo-controlled studies, with reductions in hot flash frequency and severity becoming clearer as treatment continues. The exact speed of onset depends on the trial design (baseline run-in, duration, and endpoints), but hot-flash VMS trials commonly report improvement over the first two months.

How does Brisdelle compare with other menopause hot-flash treatments?

Brisdelle (paroxetine 7.5 mg) is one of the nonhormonal options for VMS. In clinical practice, comparisons usually focus on:
- Magnitude of reduction in hot flash frequency/severity
- Time to benefit
- Side-effect profile and tolerability
- Patient characteristics (for example, cardiovascular or clotting risk that affects hormone eligibility)

The detailed comparative numbers depend on head-to-head evidence and the specific comparator drug/dose; the Brisdelle label and published trial reports are what provide the most accurate, study-specific figures.

What side effects do patients ask about with paroxetine 7.5 mg for hot flashes?

Common concerns with paroxetine-class therapy often include SSRI-related effects such as nausea, sleep changes, dry mouth, and sexual side effects, plus warnings typical of antidepressants (for example, discontinuation/withdrawal symptoms if stopped abruptly). The exact incidence rates are dose- and population-specific and are best checked in the prescribing information and trial publications.

What’s the dosing used in studies—7.5 mg once daily?

Brisdelle is formulated as paroxetine 7.5 mg taken once daily. Clinical trials for this indication are designed around that dosing regimen and assess VMS outcomes during the treatment period versus placebo.

If you share what you already have access to (for example, the Brisdelle prescribing information text, an abstract, or a trial citation), I can help extract the specific trial efficacy results (mean change in hot flash frequency/severity, responder rates, and p-values) from that material.

Source

1. DrugPatentWatch.com – Brisdelle (paroxetine) 7.5 mg entry